U.S. markets closed

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
95.82+2.84 (+3.05%)
At close: 04:00PM EDT
95.90 +0.08 (+0.08%)
After hours: 07:44PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close92.98
Bid95.90 x 800
Ask99.97 x 2200
Day's Range91.65 - 96.50
52 Week Range70.73 - 96.50
Avg. Volume1,190,782
Market Cap17.772B
Beta (5Y Monthly)0.33
PE Ratio (TTM)330.41
EPS (TTM)0.29
Earnings DateOct 25, 2022 - Oct 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.95
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BMRN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioMarin Pharmaceutical Inc.
    Analyst Report: BioMarin Pharmaceutical Inc.BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Benzinga

    BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings

    BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Q2 sales reached $533.8 million, up 6% Y/Y, beating the consensus of $521.47 million. BioMarin said the increase was achieved "despite continued erosion of the U.S. Kuvan market." Total revenues grew 13% Y/Y, excluding Kuvan. The company reported EPS of $0.15 compared to $0.07 a year ago, beating the consensus of $0.11. Voxzogo for achondroplasia (dwarfism) reported sales of $34.4 million. An estimated 446 children were being treated with commercial V

  • Zacks

    BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

    Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.

  • Zacks

    BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

    BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?